Mediwound Ltd (NASDAQ:MDWD) Short Interest Update

Mediwound Ltd (NASDAQ:MDWD) saw a large growth in short interest in July. As of July 31st, there was short interest totalling 191,100 shares, a growth of 10.3% from the June 30th total of 173,300 shares. Approximately 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 72,600 shares, the days-to-cover ratio is currently 2.6 days.

Shares of NASDAQ:MDWD traded down $0.16 during trading hours on Wednesday, hitting $3.01. The company’s stock had a trading volume of 38,900 shares, compared to its average volume of 190,528. Mediwound has a 52 week low of $2.55 and a 52 week high of $6.75. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.99 and a quick ratio of 3.79. The firm has a market capitalization of $86.70 million, a P/E ratio of -6.14 and a beta of 0.49. The company’s fifty day moving average is $3.24.

Mediwound (NASDAQ:MDWD) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.03. Mediwound had a negative net margin of 18.43% and a negative return on equity of 383.19%. The business had revenue of $20.75 million during the quarter, compared to analyst estimates of $7.03 million. Equities research analysts forecast that Mediwound will post -0.59 EPS for the current year.

MDWD has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on shares of Mediwound in a report on Monday, August 5th. They set a “buy” rating and a $5.50 price objective for the company. ValuEngine upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Oppenheimer decreased their price objective on shares of Mediwound from $15.00 to $7.00 and set an “outperform” rating for the company in a report on Wednesday. Finally, Zacks Investment Research upgraded shares of Mediwound from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $7.25.

Large investors have recently bought and sold shares of the company. Marshall Wace LLP bought a new stake in shares of Mediwound in the 1st quarter valued at about $93,000. Delek Group Ltd. bought a new stake in shares of Mediwound in the 1st quarter valued at about $141,000. Sargent Investment Group LLC raised its holdings in shares of Mediwound by 114.8% in the 2nd quarter. Sargent Investment Group LLC now owns 29,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 15,500 shares in the last quarter. Oppenheimer & Co. Inc. raised its holdings in shares of Mediwound by 6.5% in the 1st quarter. Oppenheimer & Co. Inc. now owns 32,800 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 2,000 shares in the last quarter. Finally, Deutsche Bank AG raised its holdings in shares of Mediwound by 73.5% in the 4th quarter. Deutsche Bank AG now owns 39,740 shares of the biopharmaceutical company’s stock valued at $161,000 after purchasing an additional 16,840 shares in the last quarter. Institutional investors and hedge funds own 31.16% of the company’s stock.

About Mediwound

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Further Reading: How are institutional investors different from individual investors?

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply